Pa Notification Dry Eye Disease
Defines UnitedHealthcare Pharmacy clinical notification (prior authorization) coverage criteria for specific prescription ophthalmic therapies for dry eye disease or keratoconjunctivitis sicca (Cequa, Miebo, Restasis, Restasis MultiDose, Tryptyr, Tyrvaya, Vevye, Xiidra), including initial authorization, reauthorization, prohibited concomitant use, authorization duration, and additional clinical/billing rules.
Tryptyr added to the policy.
Initial and reauthorization approval period standardized to 12 months.
Concomitant therapy prohibition added.
Miebo and Vevye added to criteria.
Tyrvaya previously added to policy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.